V
VerAvanti
VerAvanti is using advanced science and patented technology
About VerAvanti
VerAvanti Inc. is a medtech startup focused on developing advanced imaging technology for cardiac interventions. The company specializes in a sub-millimeter Scanning Fiber Endoscope that provides real-time, high-definition images of the intravascular anatomy. This innovative device allows cardiac interventionists to see the inside surface of arteries, enabling them to recommend life-saving treatments during intravascular procedures. VerAvanti's technology is particularly valuable in identifying the source of ischemic strokes and other cardiovascular events, which are often unclear in origin. By illuminating obscured defects and imperfections in the endothelium, or the cells lining the vessels, the endoscope helps in proactively planning patient therapies to reduce recurrence and other adverse events.
VerAvanti operates in the medical technology market, primarily serving cardiac interventionists and healthcare providers dealing with cardiovascular diseases. The company's business model revolves around the development, manufacturing, and sale of its proprietary endoscopic devices. Revenue is generated through the direct sale of these devices to hospitals, clinics, and medical professionals.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Bothell, United States
- Employees
- 17
- Open positions
- None listed
- Dealroom signal
- 77.3/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Risk Management, Cardiology and cardiovascular, Medical Imaging, Spinout, DT and LS, science-based
- Technology
- Deep Tech
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Oct 2025 | $5M | $140M | Undisclosed | ↗ |
| SERIES A✓Equity / VC | Mar 2025 | $28M | $112M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for VerAvanti is 920 monthly website visits, down 34.3% over the last three months. VerAvanti's team declined 5.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors2 additional known investors
University of Washington
Small Business Innovation Research
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about VerAvanti on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See VerAvanti’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.